soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025

soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Reduces Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the Randomized soul trial oral semaglutide cardiovascular

Name: soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 Reduces Events in People with Type 2 Diabetes with Atherosclerotic Cardiovascular and/or Chronic Kidney Disease: Primary Results From the Randomized soul trial oral semaglutide cardiovascular
Brand: coasta-de-azur.fr
SKU: 57997900170
Price: 21.92 USD
Availability: InStock
Rating: 4.722700000000001 (12 reviews)

SKU: 57997900170

4.7

USD21.92 USD48.92

Pay in 4 interest-free payments of $5.48 Learn more

Shipping Estimate
USA

USA

CAN

Ships within 48 hours · Estimated delivery Aug 7 - Aug 12

Description

Clinical Performance: SUSTAIN Trial Results In the SUSTAIN-7 trial (N=1,201), patients with type 2 diabetes randomized to semaglutide 1 mg once weekly lost a mean of 6.5 kg at 40 weeks compared to 3.0 kg with dulaglutide 1.5 mg 2